Persistent Helicobacter pylori Infection: An Insight to the Limitations of Current Clinical Practice

Anabel Liyen Cartelle,Pearl Princess Uy,Tara E Koehler,John Erikson L Yap

DOI: https://doi.org/10.7759/cureus.12309

2020-12-26

Cureus

Abstract:The discovery of the pathological role of <i>Helicobacter pylori</i> in various disease states, such as peptic ulcer disease (PUD) and Mucosa Associated Lymphoid Tissue (MALT) lymphoma, was ground-breaking in the field of gastroenterology. Given the potentially dire clinical implications of chronic <i>H. pylori</i> infection, it is important to achieve complete eradication. More importantly, the rising prevalence of <i>H. pylori</i> antimicrobial resistance, similar to other pathogens world-wide, is of particular concern. Despite evidence supporting the growing threat of antimicrobial resistance, clinically, it is also important to survey just how much of the failed treatment is truly a reflection of resistance versus poor treatment adherence. In this report, we detail the case of a 64-year-old female who was previously given six treatment courses for persistent <i>H. pylori</i> infection. Successful eradication was achieved with rifabutin triple therapy consisting of high-dose amoxicillin and strict adherence monitoring by a clinical pharmacist. This case highlights the importance of patient education, medication reconciliation, and close monitoring to ensure successful treatment of persistent <i>H. pylori</i> infection.